Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jessica Noble

Nurse Practitioner, Primary Care Kennewick, WA Nurse Practitioner

NPI 1447800438 CMS profile 10747504

8479 W Clearwater Ave Unit 120, Kennewick, WA 99336

Open in the dashboard

General payments

$1,718

87 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jessica Noble of Kennewick, WA is reported in the CMS Open Payments database as having received $1,718 across 87 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $311 15
2024 General $191 11
2023 General $405 20
2022 General $488 25
2021 General $323 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jessica Noble
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Jessica Noble were reported at $311. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Jessica Noble Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $323 $137 $39–$445 $132
2022 $488 $139 $44–$421 $149
2023 $405 $163 $53–$481 $160
2024 $191 $176 $54–$511 $164
2025 $311 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $217 11 payments
  2. AstraZeneca Pharmaceuticals LP $169 10 payments
  3. Novo Nordisk Inc $124 8 payments
  4. Medtronic, Inc. $108 5 payments
  5. Pfizer Inc. $107 5 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $93 4 payments
  7. GlaxoSmithKline, LLC. $90 4 payments
  8. Amgen Inc. $80 4 payments
  9. Organogenesis Inc. $80 3 payments
  10. Sunovion Pharmaceuticals Inc. $75 4 payments
  11. Other $575 29 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,718 87 payments
Products named General payments · program years 2021–2025
  1. QULIPTA $125 6 payments
  2. NURTEC ODT Pain $107 5 payments
  3. NURTEC ODT Primary Care $93 5 payments
  4. JARDIANCE $93 4 payments
  5. PAXLOVID $92 4 payments
  6. RYBELSUS $79 5 payments
  7. Ozempic $79 5 payments
  8. GEMTESA $75 4 payments
  9. NUZYRA $62 3 payments
  10. EVENITY $59 3 payments
  11. Other $1,144 56 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 52 drugs

Part D claims

1,366

Median for Nurse Practitioner: 389

Drug cost

$118,821

Median for Nurse Practitioner: $21,885

Branded share of claims

18.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 40 $59,147
Trulicity Dulaglutide Brand 19 $18,825
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 17 $13,642
Eliquis Apixaban Brand 13 $8,230
Lidocaine Generic 16 $2,200
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 14 $1,717
Propranolol Hcl Er Propranolol Hcl Brand 30 $1,016
Pregabalin Generic 41 $1,012
Albuterol Sulfate Hfa Albuterol Sulfate Brand 23 $907
Levothyroxine Sodium Generic 84 $852

The 10 drugs with the highest cost, of 52 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$25,366

Medicare's payments for the services billed

Medicare patients

130

Average age 76

Services billed

283

88 women, 42 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Diabetes 31%
Chronic kidney disease 21%
Depression 20%
Osteoporosis 20%
COPD 18%
Ischemic heart disease 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
  • Paratek Pharmaceuticals, Inc. $19
$19 — —
LOKELMA
  • AstraZeneca Pharmaceuticals LP $16
$16 — —
NURTEC ODT
  • PFIZER INC. $16
$16 — —
ELIQUIS
  • PFIZER INC. $8
$8 13 —
PAXLOVID
  • PFIZER INC. $8
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

87 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record